SALT LAKE CITY--(BUSINESS WIRE)--
BSD Medical (BSDM) today announced that President and Chief Executive Officer Harold Wolcott was recently interviewed by The Wall Street Transcript (TWST). Mr. Wolcott’s interview appeared in the publication’s August 5, 2013, Medical Devices Report. The full interview is available on BSD Medical’s web site at http://www.bsdmedical.com/international/company_news.php. The full Medical Devices Report can be acquired through contacting The Wall Street Transcript (212-952-7400 or http://www.twst.com/report/1996-medical-devices).
In the interview, Mr. Wolcott discusses BSD Medical’s pioneering medical device systems that utilize heat therapy for the treatment of cancer. BSD Medical’s two approaches, microwave ablation and hyperthermia, have made the treatment of cancer less invasive and more cost effective. The MicroThermX® Microwave Ablation System (MicroThermX) delivers stand-alone ablation therapy that utilizes microwave energy to treat diseased cancerous tissue. A MicroThermX treatment usually takes 10 to 15 minutes and may allow the patient to return home the same day. Hyperthermia therapy is used to increase the effectiveness of radiation and/or chemotherapy for the treatment of certain tumors.
In addition to BSD Medical’s technology, Mr. Wolcott spoke about BSD’s recent distribution agreement for the MicroThermX with Terumo Europe NV. He noted that the agreement with Terumo is a historic milestone for the company and further validates the many medical advantages of the company’s innovative microwave ablation technology.
Mr. Wolcott said of the recent interview with TWST, “It is an exciting time at BSD Medical and we are thrilled to share our story with the readers of The Wall Street Transcript as well as with the larger professional investment community.”
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
About the Wall Street Transcript
The Wall Street Transcript (“TWST”) is a financial interview transcripts publication and Web site that has been in business for over 40 years. TWST interviews public company CEOs, equity analysts and money managers in a wide variety of industries, and publishes the transcripts of these interviews on the Web at http://www.twst.com and in a bi-weekly print edition.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
- Health Care Industry
- Wall Street